PTC Therapeutics/$PTCT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About PTC Therapeutics
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Ticker
$PTCT
Sector
Primary listing
Employees
939
Headquarters
Website
PTC Therapeutics Metrics
BasicAdvanced
$5.4B
8.80
$7.72
0.55
-
Price and volume
Market cap
$5.4B
Beta
0.55
52-week high
$69.88
52-week low
$35.95
Average daily volume
1M
Financial strength
Current ratio
203.806
Quick ratio
3.498
Long term debt to equity
-1,153.263
Total debt to equity
-1,202.721
Interest coverage (TTM)
5.18%
Profitability
EBITDA (TTM)
894.861
Gross margin (TTM)
68.30%
Net profit margin (TTM)
35.65%
Operating margin (TTM)
49.11%
Effective tax rate (TTM)
5.54%
Revenue per employee (TTM)
$1,880,000
Management effectiveness
Return on assets (TTM)
23.81%
Return on equity (TTM)
-106.04%
Valuation
Price to earnings (TTM)
8.8
Price to revenue (TTM)
2.993
Price to book
-26.11
Price to tangible book (TTM)
-12.46
Price to free cash flow (TTM)
7.757
Free cash flow yield (TTM)
12.89%
Free cash flow per share (TTM)
8.757
Growth
Revenue change (TTM)
96.00%
Earnings per share change (TTM)
-222.38%
3-year revenue growth (CAGR)
41.86%
10-year revenue growth (CAGR)
51.02%
3-year earnings per share growth (CAGR)
-0.48%
10-year earnings per share growth (CAGR)
7.29%
What the Analysts think about PTC Therapeutics
Analyst ratings (Buy, Hold, Sell) for PTC Therapeutics stock.
Bulls say / Bears say
The FDA’s July 28, 2025 approval of Sephience™ (sepiapterin) for phenylketonuria (PKU) broadens PTC’s commercial portfolio beyond DMD products, with Jefferies projecting peak sales of $741 million by 2030, marking a significant new revenue stream (Reuters)
PTC delivered full‐year 2024 total revenue of $814 million—surpassing its guidance—which underscores its ability to grow top‐line sales across its rare disease portfolio (Investing.com)
As of June 30, 2025, PTC held $1.99 billion in cash, cash equivalents and marketable securities, reinforcing its strong liquidity position to fund ongoing R&D, commercial launches and strategic partnerships without immediate capital needs (SEC 10-Q)
The FDA’s Complete Response Letter for vatiquinone in Friedreich’s ataxia delays a key pipeline asset and necessitates additional clinical trials before resubmission, undermining near‐term growth prospects and triggering a >5% share decline after the announcement (Reuters)
PTC’s legacy Duchenne muscular dystrophy therapies are facing headwinds, as Translarna and Emflaza revenues decline due to patent expirations and regulatory scrutiny, constraining the company’s established cash flows amidst a transition toward newer products (Reuters)
Despite Sephience’s approval, PTC’s pipeline beyond this single blockbuster remains underdeveloped, with other candidates—such as vatiquinone—stalled, intensifying reliance on one major product and heightening execution risk (S&P Global Market Intelligence)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
PTC Therapeutics Financial Performance
Revenues and expenses
PTC Therapeutics Earnings Performance
Company profitability
PTC Therapeutics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PTC Therapeutics stock?
PTC Therapeutics (PTCT) has a market cap of $5.4B as of November 05, 2025.
What is the P/E ratio for PTC Therapeutics stock?
The price to earnings (P/E) ratio for PTC Therapeutics (PTCT) stock is 8.8 as of November 05, 2025.
Does PTC Therapeutics stock pay dividends?
No, PTC Therapeutics (PTCT) stock does not pay dividends to its shareholders as of November 05, 2025.
When is the next PTC Therapeutics dividend payment date?
PTC Therapeutics (PTCT) stock does not pay dividends to its shareholders.
What is the beta indicator for PTC Therapeutics?
PTC Therapeutics (PTCT) has a beta rating of 0.55. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.